Skip to main content
Premium Trial:

Request an Annual Quote

Microbiologics Acquires Phthisis Diagnostics

NEW YORK (GenomeWeb News) – Microbiologics has acquired Phthisis Diagnostics, a maker of molecular standards and diagnostics, for an undisclosed amount.

Microbiologicals current focus is on lyophilized microorganism products for quality control of microbiological testing, but the molecular products line of Phthisis will form the basis of a new molecular products division.

The acquisition will "lay the foundation for Microbiologics to design and launch a broad collection of molecular products and custom services," Brad Goskowicz, CEO of the St. Cloud, Minn.-based firm, said in a statement. He added that the deal "will expand our range of biomaterials to include viruses and other hard to grow microorganisms."

Phthisis has developed a line of control standards for molecular laboratories called G-Sphere. This line of synthetic standard genes can provide stable, consistent, abundant controls for molecular fingerprinting of pathogens important to public health, among other applications, according to Charlottesville, Va.-based Phthisis.

Crystal Icenhour, president and chief science officer of Phthisis, will also serve as an advisor to Microbiologics as it develops its new division and adopts Phthisis' technology. "[T]his longer established company will have the structure to take these products much further than our smaller company could have," Icenhour said in a statement.

Supporting its new molecular diagnostics direction, Microbiologics also said that it has hired a VP of Products and Services, Brian Beck. He joins the firm from ATCC, where he managed the microbiology collection and associated bioservices.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more